Note: This is one of the clinical studies that I was proud to participate on the Patient Advisory Board. – Alan
In real-world clinical practice, heterogeneous patient experiences occur during and after direct acting antiviral (DAA) therapy, and symptom improvement is often more pronounced in younger patients, according to a multicenter observational study published in the Journal of Hepatology.1
Patients with hepatitis C virus (HCV) infection often report various symptoms such as neuropsychiatric, somatic, and gastrointestinal symptoms that they attribute to the virus infection.2-4 Studies have demonstrated that health-related quality of life and other patient-reported outcomes improve during DAA therapy,5-7 but a comprehensive analysis of changes in symptoms and functioning during and after DAA therapy for chronic HCV has not been conducted for patients treated in real-world clinical settings. Therefore, researchers in the United States evaluated patient-reported outcomes in a diverse cohort of 1564 patients with HCV treated with commonly-prescribed DAAs (63% were prescribed sofosbuvir/ledipasvir; 21%, sofosbuvir/velpatasvir; 11%, grazoprevir/elbasvir; and 5%, paritaprevir/ombitasvir/ritonavir+dasabuvir).1 Overall, they found that these patients did not experience significant changes in baseline symptoms during treatment. However, they observed a full range of experiences, with some patients experiencing substantial symptom improvement, others experiencing less improvement, and some even experiencing a worsening of symptoms. Of these patients, 1346 were cured of HCV and experienced improvements in fatigue, sleep disturbance, and functional well-being and trends for improvement in pain and depression. However, 64 patients were not cured and experienced minimal improvement.